Detailed narrative
Commercial Momentum and Strategy
Fortrea reported $720.4 million in net new business for Q2 FY26, achieving a book-to-bill ratio of 1.06x, marking the fourth consecutive quarter above 1.0x. First half 2026 net new business awards increased 19% year-over-year, driven by a diversified client base including new and existing biotech customers. The commercial strategy focuses on "reach, relevance, and repeat" to expand customer relationships, offer differentiated expertise, and secure follow-on work.
Operational Excellence and Technology Integration
The company continues to focus on project management, site activation, enrollment, and quality, with on-time delivery remaining a key differentiator. Fortrea Intelligent Technology (FIT), an AI-driven clinical trial intelligence ecosystem, was launched externally in April. Early results from the CRA mobile app, deployed in over 50 countries, show efficiency gains, such as reducing site visit preparation time by nearly 30 minutes per visit in one study in Spain.
Financial Discipline and Cost Management
Fortrea delivered $678.2 million in revenue and $58.7 million in adjusted EBITDA for Q2 FY26. The company achieved $18 million in new gross cost savings in the quarter, bringing the year-to-date total to $34 million. Net cost savings for the quarter were $10 million, totaling $19 million year-to-date, reflecting ongoing operational efficiencies and cost optimization initiatives.
CFO Transition and Leadership Continuity
New CFO Jason Madlock is currently unable to act due to a restrictive covenants proceeding. Board member David Smith, former CFO of Charles River Laboratories, has stepped in as interim CFO, ensuring continuity in financial leadership. Jill McConnell, the outgoing CFO, was recognized for her 8 years of service, including leading the company's spin-off and building its financial foundation.
Market Environment and Competitive Landscape
Management noted a continued improvement in the broader demand backdrop, with more constructive customer engagement across both pharma and biotech, and normalized large pharma procurement processes. While the industry remains competitive, the "temporal irrational behavior" in pricing and FSP observed in 2025 has subsided, leading to a more rational pricing environment in 2026.
Capital Allocation and Balance Sheet Strength
Fortrea's capital allocation priorities remain investing in organic growth, improving productivity, and continuing to delever. The company has paid down approximately 35% of its original debt since the spin-off. Operating cash flow was positive $28.9 million and free cash flow was positive $19.9 million in Q2 FY26, with available liquidity exceeding $0.5 billion.